MEIOB

Across TCGA pan-cancer cohorts, MEIOB Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MEIOB data layer compared with 24 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher MEIOB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MEIOB expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, STAD, and LUAD are the cancer types where MEIOB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.095	0.830	<.001	34	view →
STAD	DFS	Median	All	0.149	0.710	<.001	30	view →
LUAD	DFS	Median	All	0.261	0.678	.004	12	view →
KIRC	OS	Median	All	0.178	0.655	.042	6	view →
UCEC	DFS	Median	All	1.000	0.831	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MEIOB–CESC (OS)

Open the CESC breakdown →